Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Palatin extends license option to bremelanotide in Europe
Under the option agreement, the company has received a $1m, non-refundable option fee. If not exercised, the option that is subject to certain contingencies will expire on 30
Under the option agreement, the company has received a $1m, non-refundable option fee. If not exercised, the option that is subject to certain contingencies will expire on 30
The 808 patent expires on 01 September 2015 and claims a process for manufacturing the active ingredient of the company’s relapsing-remitting multiple sclerosis (RRMS) product, Copaxone (glatiramer acetate
The joint research facility will be located at AstraZeneca’s new research and development (R&D) center in Cambridge, scheduled to be completed in 2016. The AstraZeneca MRC UK Centre
The new vaccine will be manufactured at a newly-established facility at the company’s Hikari Plant in Hikari City, Yamaguchi Prefecture. In 2010, Takeda and Baxter International have entered
The transaction, which is with three connected entities, also includes GSK divesting a non-core brand and a manufacturing facility in the country. GSK has also divested its Insto
Alprolix is indicated for the control and prevention of bleeding episodes, perioperative (surgical) management and routine prophylaxis in adults and children with haemophilia B. The company said that
Pergoveris is a combination of recombinant human follicle stimulating hormone (r-hFSH) and recombinant human luteinizing hormone (r-hLH) delivered through subcutaneous injection. The multi-center, randomized, controlled, single-blind, parallel Espart
The approval marks a major step towards providing those who suffer from frequent heartburn broader access to a brand doctors and patients have trusted for years. Pfizer acquired
The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) had already issued a positive opinion for Latuda in January 2014. Latuda is an atypical
The capacity expansion at the plant will help in providing a reliable supply of high-quality products to meet the domestic demand for the company’s products including cardiovascular and